Literature DB >> 6313646

Thrombomodulin blocks the ability of thrombin to activate platelets.

N L Esmon, R C Carroll, C T Esmon.   

Abstract

When thrombin is complexed to the endothelial cell surface receptor thrombomodulin, it loses its procoagulant activities in that it no longer clots fibrinogen or activates factor V. Studies were initiated to determine if complex formation also blocks thrombin's other major procoagulant function, the activation of platelets. When bound to thrombomodulin, thrombin no longer induces platelets to either aggregate or release [14C] serotonin. Binding studies using 125I-labeled thrombin or diisopropyl phosphorothrombin indicate that the complex does not bind to the platelet. When thrombomodulin is added after thrombin has bound to the platelets, the thrombin rapidly redistributes onto the thrombomodulin. These data suggest that in addition to its other anticoagulant effects, thrombomodulin may also act to inhibit and/or reverse platelet activation by thrombin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6313646

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

Review 1.  New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin.

Authors:  Shannon M Bates; Jeffrey I Weitz
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

2.  Recombinant Thrombomodulin (Solulin) Ameliorates Early Intestinal Radiation Toxicity in a Preclinical Rat Model.

Authors:  Rupak Pathak; Junru Wang; Sarita Garg; Nukhet Aykin-Burns; Karl-Uwe Petersen; Martin Hauer-Jensen
Journal:  Radiat Res       Date:  2016-07-26       Impact factor: 2.841

Review 3.  The role of endothelium in the pathogenesis of diabetic microangiopathy.

Authors:  M La Selva; E Beltramo; P Passera; M Porta; G M Molinatti
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

Review 4.  Novel antithrombotic drugs in development.

Authors:  M Verstraete; P Zoldhelyi
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

5.  Thrombomodulin gene polymorphisms in brain infarction and mortality after stroke.

Authors:  Jean-Marc Olivot; Julien Labreuche; Thomas De Broucker; Odette Poirier; François Cambien; Martine Aiach; Pierre Amarenco
Journal:  J Neurol       Date:  2008-01-23       Impact factor: 4.849

Review 6.  Clinical relevance of protein C.

Authors:  I Pabinger
Journal:  Blut       Date:  1986-08

7.  Promotion of lung tumor colonization in mice by the synthetic thrombin inhibitor (no. 805) and its reversal by leech salivary gland extracts.

Authors:  A Iwakawa; T B Gasic; E D Viner; G J Gasic
Journal:  Clin Exp Metastasis       Date:  1986 Jul-Sep       Impact factor: 5.150

8.  Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation.

Authors:  C B Glaser; J Morser; J H Clarke; E Blasko; K McLean; I Kuhn; R J Chang; J H Lin; L Vilander; W H Andrews; D R Light
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

9.  Thrombomodulin expression by human keratinocytes. Induction of cofactor activity during epidermal differentiation.

Authors:  T J Raife; D J Lager; K C Madison; W W Piette; E J Howard; M T Sturm; Y Chen; S R Lentz
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

10.  Identification of the predominant glycosaminoglycan-attachment site in soluble recombinant human thrombomodulin: potential regulation of functionality by glycosyltransferase competition for serine474.

Authors:  B Gerlitz; T Hassell; C J Vlahos; J F Parkinson; N U Bang; B W Grinnell
Journal:  Biochem J       Date:  1993-10-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.